Strategic CMC & Technical Operations Leadership

Delivering IND‑ready packages and late‑stage process optimization through practical, science‑driven strategy. We align molecule, process, and organization to achieve accelerated clinical milestones and robust regulatory outcomes.

Start a conversation

Approach

First Principles CMC partners with emerging biotech teams to convert innovation into reliable, manufacturable therapies. We build technical and operational systems that scale with your company—ensuring disciplined execution, integrated control strategies, and regulatory credibility from IND to BLA.

Principles

  • Science‑first, outcome‑oriented decision making
  • Clear operational frameworks tied to program milestones
  • Stage‑appropriate risk management and control strategies
  • Collaborative leadership that builds technical teams and partnerships

Core Capabilities

CMC Strategy & Program Leadership

Designing and scaling Technical Operations organizations aligned with company growth stage—from lean start‑up execution to late‑stage readiness.

Manufacturing & Tech Ops Build‑Out

Global CDMO selection, tech transfer, and governance frameworks that ensure reliable supply and capital‑efficient execution.

Control Strategy & QbD

Risk‑based QbD frameworks ensuring deep process understanding, consistent product quality, and accelerated regulatory acceptance.

IND / IMPD / CTA

Coordinated authoring and review of global CMC submissions—IND/IMPD/CTA through late‑stage readiness—with technically sound, defensible documentation.

First‑in‑Human Execution

Translating research to GMP with lifecycle optimization, comparability, and validation planning aligned to accelerated approval options.

CDMO Network Leadership

Global MSAT leadership and deviation/CPV frameworks that preserve regulatory posture through commercialization.

Representative Experience

  • Built and scaled Technical Operations organization from inception to a 16‑person, high‑performance team.
  • Delivered IND‑ready packages and accelerated first‑in‑human programs across biologics and bioconjugates.
  • Established integrated control strategies, late‑stage optimization plans, and PPQ/comparability approaches for global readiness.
  • Directed lifecycle CMC strategy and submissions across modalities (IND → BLA/MAA) with defensible, audit‑ready documentation.

Delivery Signals

  • IND-ready packages and cross-functional CMC integration
  • Scalable, phase-appropriate manufacturing systems aligned to growth stage
  • Capital-efficient execution frameworks across CDMOs and partners
  • Robust control strategies supporting late-stage optimization and validation
  • Lifecycle regulatory readiness from IND → BLA / MAA

About

Benjamin Hutchins, PhD is a Technical Operations executive with 15+ years of experience in biologics and ADC development. He builds teams, systems, and strategies that convert science into reliable clinical and commercial supply, with expertise in CMC strategy, process optimization, and lifecycle regulatory design.